Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

942 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safe and potent anti-CD19 CAR T-cells with shRNA-IL-6 gene silencing element in patients with refractory or relapsed B-cell acute lymphoblastic leukemia.
Ma JF, Yan JW, Liu MJ, Yan CL, Tang XW, Qiu HY, Miao M, Han Y, Li LM, Kang LQ, Xu N, Yu Z, Tan JW, Zhu HJ, Jia X, Zhang ZZ, Wang M, Dai HP, Yu L, Xue SL, Wu DP, Gong WJ. Ma JF, et al. Among authors: li lm. Hemasphere. 2024 Oct 7;8(10):e70007. doi: 10.1002/hem3.70007. eCollection 2024 Oct. Hemasphere. 2024. PMID: 39380843 Free PMC article.
CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory/relapsed B-cell acute lymphoblastic leukemia.
Liu J, Xu M, Zhang X, Zhang Z, Zhong T, Yu H, Fu Y, Meng H, Feng J, Zou X, Han X, Kang L, Yu L, Li L. Liu J, et al. Heliyon. 2024 Jul 1;10(13):e33937. doi: 10.1016/j.heliyon.2024.e33937. eCollection 2024 Jul 15. Heliyon. 2024. PMID: 39055833 Free PMC article.
Characteristics and clinical influence factors of arsenic species in plasma and their role of arsenic species as predictors for clinical efficacy in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.
Guo M, Zhou J, Fan S, Li L, Chen H, Lin L, Zhao Q, Wang X, Liu W, Wu Z, Hai X. Guo M, et al. Expert Rev Clin Pharmacol. 2021 Apr;14(4):503-512. doi: 10.1080/17512433.2021.1893940. Epub 2021 Mar 8. Expert Rev Clin Pharmacol. 2021. PMID: 33678104
Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations.
Li L, Zhang X, Yu H, Zhang M, Xu M, Liu J, Fu Y, Meng H, Lyu C, Li X, Zhou J. Li L, et al. Onco Targets Ther. 2018 Oct 12;11:6863-6870. doi: 10.2147/OTT.S161919. eCollection 2018. Onco Targets Ther. 2018. PMID: 30349319 Free PMC article.
942 results